

**CONCETTA POTENZA**  
**Curriculum Vitae**

Place LATINA  
Date 13/11/2018

**Part I – General Information**

Full Name	CONCETTA POTENZA
Date of Birth	12 OCT 1960
Place of Birth	ROME
Citizenship	ITALIAN
Permanent Address	VIA DELLE FRATTE DI TRASTEVERE ROMA
Mobile Phone Number	3388126338
E-mail	concetta.potenza@uniroma1.it
Spoken Languages	ITALIAN, ENGLISH

**Part II – Education**

Type	Year	Institution	Notes (Degree, Experience,...)
University graduation	1985	SAPIENZA UNIVERSITY	MEDICAL DEGREE cum laude
Post-graduate studies	1989	SAPIENZA UNIVERSITY	Post graduate cum laude in Dermatology and Venereology
PhD			
Specialty			
Pre-doctorate training			
Licensure 01			
Licensure 02			

**Part III – Appointments****IIIA – Academic Appointments**

1998-1999	Master in Management and Public Health, Faculty of Medicine and Surgery, Catholic University of Rome and Pontificia Universitas Lateranensis of Vatican City, Italy
1997-1999	Postgraduate Research Program "Health Management and Evidence Based Dermatology", IRCS, Rome, Italy, supported by Ministry of Health
1986-1989	Clinical and research fellowship "S. Gallicano Dermosifilopathic Hospital", Rome, Italy



- 1986 Assistant of Prof. Bonmassar (Director of IDI Melanoma Center). Laboratory of the National Institute of Diabetes and Digestive and Kidney Disease at National Institute of Health of Bethesda
- 1986 Visiting Scientist, Laboratory of the National Institute of Diabetes and Digestive and Kidney Diseases of National Institute of Health of Bethesda Washington D.C. USA (Chief G.D. Aurbach MD)

#### **Part IV – Teaching experience**

- 2006 - present Dermatology at Sapienza University, I Faculty of Medicine and Surgery. Department of Medical-Surgical Sciences And Biotechnologies, Polo Pontino Italy.
- 2006 - present Master of Esthetic Medicine, University of San Marino, San Marino.
- 2006 - 2009 Dermatology at Nursery School, Sapienza University of Rome, I Faculty of Medicine and Surgery - Polo Pontino, Italy.
- 2006 - 2007 Member of Commission of University Exam on Dermatology, Dentistry School, Sapienza University of Rome
- 2001- 2007 Dermatology at Nursery School, Cassino, Sapienza University, I Faculty of Medicine and Surgery. Rome, Italy.
- 2001- 2007 Oncodermatology and Dermatovenereological Diseases, Sapienza University, I Faculty of Medicine and Surgery. Department of Dermatology and Plastic Surgery, Rome, Italy.
- 2000 - present Epidemiology and Statistics in Dermatology, Postgraduate school. Department of Dermatology and Plastic Surgery, Sapienza University of Rome Italy

#### **Part V - Society memberships, Awards and Honors**

- 2005- Member, Association Italian Dermatologist (ADOI)
- 2005- Member, Italian Society of Dermatology (SIdMaST)
- 2005- Member, Italian Acne Board (IAB)
- 2006- Organizer and Coordinator of more than 30 National workshops on main topics: Inflammatory skin diseases (psoriasis, acne), Immunomediated skin diseases, Melanoma and no melanoma skin cancer, Biological Therapy. Conferences on Dermatology and Public Health.
- 2009- Member of Postgraduate School Committee. Department of Dermatology and Plastic Surgery, Sapienza University of Rome Italy.
- 2009- Review dermatologist panel member, Sapienza University, Ministry of Education, Universities and Research (MIUR), Italy
- 2012 Director and Organizer of International Conference "Optimal results in psoriasis treatment with biologics: from the Patient selection to Long Term Management".
- 2013- International Scientific Board of scientific journal "Senses and Sciences", Sapienza University, Italy.
- 2013- Member Accademia Medica Romana of Public Health (Scientia et Studium pro Actione in Re Publica).
- 2015- Member of International Association of Ecodermatology (SKINECO)
- 2016- Member of Board for "24<sup>th</sup> WORLD CONGRESS OF DERMATOLOGY" - MILAN June 2019
- 2017- Member of European Academy of Dermatology and Venereology (EADV membership No°00020646)
- 2017- Member of European Hidradenitis Suppurativa Foundation e.V. (EHSF)



**Part VI - Funding Information [grants as PI-principal investigator or I-investigator]**

**NCT02394561**

**Potenza (PI) Role: Principal Investigator**

**03/2015-09/2016**

A 24-week, Multicenter, prospective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety Profile of Secukinumab 300 mg in Cw6-negative and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME). A study to evaluate the differences in the efficacy and safety of secukinumab between Cw6-negative and Cw6-positive patients with moderate to severe plaque-type psoriasis. Other Study ID Numbers: CAIN457AIT01.

**NCT02752776**

**Potenza (PI) Role: Principal Investigator**

**10/02/2016**

A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. (PROSE). An open-label, prospective, non-randomized, multicenter study to evaluate clear skin effect on health-related quality of life outcomes at 16 and 52 weeks in patients with moderate to severe plaque psoriasis treated with secukinumab 300 mg s.c. with or without previous exposure to systemic therapy. Other Study ID Numbers: CAIN457A3401.

**NCT02684357**

**Potenza (PI) Role: Principal Investigator**

**16/02/2016**

BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis.

**Completed Research Support**

**NCT01358578**

**Potenza (PI) Role: Principal Investigator**

**02/2015-01/2016**

A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis. This study assessed the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis. Other Study ID Numbers: CAIN457A2303.

**NCT01100034**

**Potenza (PI) Role: Principal Investigator**

**04/2010-09/2016**

A Long-term, Prospective, Observational Cohort Study Of The Safety And Effectiveness Of Etanercept In The Treatment Of Paediatric Psoriasis Patients In A Naturalistic Setting: A Post-authorization Safety Study (PURPOSE). The aim of this study was to assess the safety and effectiveness of etanercept for the treatment of pediatric psoriasis in Europe. Other Study ID Numbers: 0881X1-4654.

**NCT01964443**

**Potenza (PI) Role: Principal Investigator**

**09/2013-12/2015**

**Clinical Assessment and Psychosocial Impact of Psoriasis (EPIDEPSO).**

The purpose of this study was to explore the impact of plaque psoriasis on the different dimensions of patient life including psychological disorders, different types of addictions, and their consequences on health-related quality of life and socioeconomic parameters at baseline (cross-sectional part) and during the initial years of the psoriasis disease (longitudinal part). Other Study ID Numbers: CR100972 CNT01275PSO4034.



## NATIONAL ADVISORY BOARDS

IT 11081

Potenza (PI)

2016

HIDRAdisk Validation Study- studio epidemiologico per la validazione di un questionario sulla qualità di vita in pazienti affetti da HS

04/CE/2015

Potenza (PI)

2015

Multicentric Study on Actinic Keratosis (ONAK).

0052838/272/U.V.F./1

Potenza (PI)

2014

Multicentric Study on Retention & adherence real life to psoriasis treatment and health care efficiency (RALPH)

IT11-06

Potenza (PI)

2011

Multicentric Study "Psodisk: a new visual method for assessing the burden of psoriasis on patients"

C26A11AWMS

Della Rocca (PI) 2011

Study on "BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma"

Role: Co-investigator.

111/34

Potenza (PI)

2009

Study on "Different histopathological aspect of psoriatic plaques and different response to Etanercept Treatment".

IT-09-20

Potenza (PI)

2009

A multicenter cross-sectional survey: Progetto Daniele, for evaluation of impact of psoriasis on work-related problems.

C26F09LEMJ

Potenza (PI)

2009

Study on Anti-TNFalpha Drugs in Psoriasis Treatment

## UNIVERSITY PROJECTS

C26H153BSX

Potenza (PI)

2015/2017

Role of epigenetic mechanisms in psoriatic lesions. Relevance in anti-IL-17 biological therapy.

C26A14SJ5Z

Potenza (Co-Investigator)

2014

"Screening e monitoraggio della tubercolosi latente nei pazienti candidati al trattamento con farmaci biologici anti-TNF: analisi in vivo e in vitro della risposta cellulo-mediata T polifunzionale"

C26A137AMZ

Potenza (Co-Investigator)

2013

"Screening e monitoraggio della tubercolosi latente nei pazienti candidati al trattamento con farmaci biologici anti-TNF: analisi in vivo e in vitro della risposta cellulo-mediata T polifunzionale"



**Part VI - Funding Information [grants as PI-principal investigator or I-investigator]**

**NCT02394561**

**Potenza (PI) Role: Principal Investigator**

**03/2015-09/2016**

A 24-week, Multicenter, prospective study to Evaluate the PASI 90 Clinical Response Rate and the Safety Profile of Secukinumab 300 mg in Cw6-negative and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME). A study to evaluate the differences in the efficacy and safety of secukinumab between Cw6-negative and Cw6-positive patients with moderate to severe plaque-type psoriasis. Other Study ID Numbers: CAIN457AIT01.

**NCT02752776**

**Potenza (PI) Role: Principal Investigator**

**10/02/2016**

A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. (PROSE). An open-label, prospective, non-randomized, multicenter study to evaluate clear skin effect on health-related quality of life outcomes at 16 and 52 weeks in patients with moderate to severe plaque psoriasis treated with secukinumab 300 mg s.c. with or without previous exposure to systemic therapy. Other Study ID Numbers: CAIN457A3401.

**NCT02684357**

**Potenza (PI) Role: Principal Investigator**

**16/02/2016**

BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis.

**Completed Research Support**

**NCT01358578**

**Potenza (PI) Role: Principal Investigator**

**02/2015-01/2016**

A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis. This study assessed the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis. Other Study ID Numbers: CAIN457A2303.

**NCT01100034**

**Potenza (PI) Role: Principal Investigator**

**04/2010-09/2016**

A Long-term, Prospective, Observational Cohort Study Of The Safety And Effectiveness Of Etanercept In The Treatment Of Paediatric Psoriasis Patients In A Naturalistic Setting: A Post-authorization Safety Study (PURPOSE). The aim of this study was to assess the safety and effectiveness of etanercept for the treatment of pediatric psoriasis in Europe. Other Study ID Numbers: 0881X1-4654.

**NCT01964443**

**Potenza (PI) Role: Principal Investigator**

**09/2013-12/2015**

**Clinical Assessment and Psychosocial Impact of Psoriasis (EPIDEPSO).**

The purpose of this study was to explore the impact of plaque psoriasis on the different dimensions of patient life including psychological disorders, different types of addictions, and their consequences on health-related quality of life and socioeconomic parameters at baseline (cross-sectional part) and during the initial years of the psoriasis disease (longitudinal part). Other Study ID Numbers: CR100972 CNT01275PSO4034.



## Part VII – Research Activities

Keywords	Brief Description
PSORIASIS	<p>I developed a histodynamical model, linking histological and immune-histochemical aspects to the different phases of psoriasis. I analyzed psoriatic skin during and after treatment with biological drugs (anti-Tumor Necrosis Factor alpha).</p> <p>During last years I also examined in depth psoriasis' comorbidities to find the molecular and genetic subset that links psoriasis to metabolic syndrome, inflammatory bowel diseases, celiac disease and cardiovascular disorders.</p> <p>I first published about a new method to assess the cardiovascular risk in patients affected by psoriasis, further finding an explanation to the increased risk for myocardial infarction that is observed in otherwise healthy psoriatic patients.</p> <p>My latest fields of research include the advanced pathogenesis of psoriasis and the role of interleukin-17 (IL-17), with the objective to identify clusters of patients who have different responses to anti-IL-17 treatments. I participated to a worldwide Phase III trial on a new anti-IL17 drug, including the results in a peer-reviewed scientific paper.</p> <p>For what concerns skin cancer I created a Melanoma Unit aimed to follow the oncologic patient in a multi-disciplinary setting, involving different specialists such as dermatologist, oncologist, plastic surgeon and radiotherapist. I also created a dermo-oncologic outpatient clinic for the advanced management of non-melanoma skin cancers (actinic keratosis, basal and squamous cell carcinomas etc.): the use of non-surgical treatments such as photodynamic therapy (PDT) and topical ingenol mebutate allows a significant reduction of costs for National Health System and morbidity for patients. The Department I direct is a leading center for the treatment of acne, adnexal diseases and atopic dermatitis. As a founding member of the Italian Acne Board (IAB) I conducted several research projects on acne, with special regard to the relationship between acne and diet.</p>
MELANOMA	
NMSC	
HIDRADENITIS SUPPURATIVE	
ACNE	
ATOPIC DERMATITIS	

--

## Part VIII – Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	63	PUBMED-SCOPUS	1989	2018
Papers [national]	5	PUBMED-SCOPUS	2003	2006
Books [scientific]	7	ISBN	2009	2012
Books [teaching]	5	ISBN	2007	2011

Total Impact factor	192.741
Total Citations	358
Average Citations per Product	4.287
Hirsch (H) index	12
Normalized H index*	0.36

\*H index divided by the academic seniority.



## Part IX– Selected Publications

List of the publications selected for the evaluation. For each publication report title, authors, reference data, journal IF (if applicable), citations, press/media release (if any).

### **Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.**

Talamonti M, Galluzzo M, Bernardini N, Caldarola G, Persechino S, Cantoresi F, Egan CG, Potenza C, Peris K, Bianchi L

J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1737-1744. doi: 10.1111/jdv.15077. Epub 2018 Jun 1.

IF 4.287

Cit 0

### **Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.**

Potenza MC<sup>1</sup>, Peris K<sup>2</sup>, Berardesca E<sup>3</sup>, Bianchi L<sup>4</sup>, Richetta A<sup>4,5</sup>, Bernardini N<sup>1</sup>, De Simone C<sup>2</sup>, Teoli M<sup>4</sup>, Zangrilli A<sup>4</sup>, D'epiro S<sup>5</sup>, Orsini D<sup>6</sup>, Narcisi A<sup>6,7</sup>, Chimenti S<sup>4</sup>, Costanzo A<sup>7,8</sup>.

Dermatol Ther. 2018 Jan;31(1). doi: 10.1111/dth.12565. Epub 2017 Dec 7.

IF 155

CIT 0

### **Clinical utility of ingenol mebutate in the management of actinic keratosis: perspectives from clinical practice.**

Ther Clin Risk Manag. 2018 Oct 4;14:1879-1885. doi: 10.2147/TCRM.S145779. eCollection 2018.

Skroza N<sup>1</sup>, Bernardini N<sup>1</sup>, Proietti I<sup>1</sup>, Potenza C<sup>1</sup>.

IF 1.995

CIT 0

### **A Review of the Literature of Surgical and Nonsurgical Treatments of Invasive Squamous Cells Carcinoma.**

Potenza C<sup>1</sup>, Bernardini N<sup>1</sup>, Balduzzi V<sup>1</sup>, Losco L<sup>2</sup>, Mambrin A<sup>1</sup>, Marchesiello A<sup>1</sup>, Tolino E<sup>1</sup>, Zuber S<sup>1</sup>, Skroza N<sup>1</sup>, Proietti I<sup>1</sup>.

Biomed Res Int. 2018 Apr 2;2018:9489163. doi: 10.1155/2018/9489163. eCollection 2018.

IF 2.583

CIT 0

### **Efficacy and tolerability of a lotion containing triethyl citrate, ethyl linoleate, and GT peptide-10 in the adjuvant treatment of hidradenitis suppurativa: Real-life data.**

Skroza N<sup>1</sup>, Mambrin A<sup>1</sup>, Tolino E<sup>1</sup>, Marchesiello A<sup>1</sup>, Proietti I<sup>1</sup>, Bernardini N<sup>1</sup>, Potenza C<sup>1</sup>.

Dermatol Ther. 2018 Jul;31(4):e12599. doi: 10.1111/dth.12599. Epub 2018 Apr 11.

IF 1.55

CIT 0

**Factors influencing response to ingenol mebutate therapy for actinic keratosis of face and scalp.**

Skroza N<sup>1</sup>, Proietti I<sup>1</sup>, Bernardini N<sup>1</sup>, Balduzzi V<sup>1</sup>, Mambrin A<sup>1</sup>, Marchesiello A<sup>1</sup>, Tolino E<sup>1</sup>, Zuber S<sup>1</sup>, La Torre G<sup>2</sup>, Potenza C<sup>1</sup>.

World J Clin Oncol. 2017 Oct 10;8(5):405-411. doi: 10.5306/wjco.v8.i5.405.

IF 4.34

CIT 1

**Biologic Therapies in HIV-infected Patients with Psoriasis: An Italian Experience.**

Bardazzi F<sup>1</sup>, Magnano M, Campanati A, Loconsole F, Carpentieri A, Potenza C, Bernardini N, Di Lernia V, Carrera C, Raone B, Patrizi A, Loi C.

Acta Derm Venereol. 2017 Aug 31;97(8):989-990. doi: 10.2340/00015555-2698.

IF 3.653

CIT 3

**Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study.**

Sampogna F<sup>1</sup>, Puig L<sup>2</sup>, Spuls P<sup>3</sup>, Girolomoni G<sup>4</sup>, Radtke MA<sup>5</sup>, Kirby B<sup>6</sup>, Brunori M<sup>7</sup>, Bergmans P<sup>8</sup>, Smirnov P<sup>9</sup>, Rundle J<sup>10</sup>, Lavie F<sup>7</sup>, Paul C<sup>11</sup>; EPIDEPSO Investigators.

Br J Dermatol. 2017 May;176(5):1195-1203. doi: 10.1111/bjd.15243. Epub 2017 Apr 10.

IF 6.129

CIT 4

**Cardiovascular risk in psoriatic patients detected by heart rate variability (HRV) analysis.**

Proietti I<sup>1</sup>, Raimondi G, Skroza N, Pampera R, Bernardini N, La Viola G, Nicolucci F, Tolino E, Zuber S, Scordamaglia B, Balduzzi V, Soccodato V, Potenza C.

Drug Dev Res. 2014 Nov;75 Suppl 1:S81-4. doi: 10.1002/ddr.21204.

IF 1.909

CIT 5

**Secukinumab in plaque psoriasis--results of two phase 3 trials.**

Langley RG<sup>1</sup>, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tying S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group.

N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.

IF 79.258

CIT 0



**Skin manifestations in course of celiac disease: case report and review of the literature.**

Skroza N, Proietti I, Bernardini N, Giorgio LV, Mancini MT, Nicolucci F, Pampena R, Tolino E, Zuber S, Potenza C.

Curr Pharm Des. 2014;20(7):1136-8.

IF 3.452

CIT 0

**The impact of psoriasis on work-related problems: a multicenter cross-sectional survey.**

Ayala F<sup>1</sup>, Sampogna F, Romano GV, Merolla R, Guida G, Gualberti G, Paparatti UD, Amerio P, Balato N, Potenza C; Daniele Study Group.

J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1623-32. doi: 10.1111/jdv.12233. Epub 2013 Aug 21.

IF 2.826

CIT 16

A handwritten signature in black ink, appearing to read 'Cosetta Potenza', is located in the upper right quadrant of the page.